Search Results for “dialysis” – Page 5 – media

Zdravookhraneniye 2024 Moscow Russia

Organiser: Russia ZAO Exhibition Co., LTD Time: 02 – 06 December 2024 Exhibition hall: Expocentre Exhibition Center Product categories: Diagnostic equipment: X-ray diagnostic equipment, ultrasonic diagnostic equipment, functional examination equipment, endoscopy equipment, nuclear medicine equipment, experimental diagnostic equipment, pathological diagnostic equipment, diagnostic imaging equipment, chromatographic analyzer, consulting room analyzer, dialysis and transplant surgery Treatment equipment: clinical radiology equipment; Clinical testing equipment and reagents, ward nursing equipment, surgery equipment, radiotherapy equipment, nuclear medicine treatment equipment, physical and chemical equipment, laser equipment, dialysis treatment equipment, temperature freezing equipment, first aid equipment Auxiliary equipment: disinfection and sterilization equipment, refrigeration equipment, central suction and oxygen supply system, air conditioning equipment, pharmaceutical machinery and equipment, blood bank equipment, medical data processing equipment, medical video and photography equipment, medical air pump system cosmetic equipment; Ophthalmic equipment and treatment technology and materials, dental equipment and instruments, dental repair systems and instruments, oral plastic surgery materials and tools, dental ...
- Source: drugdu
- 181
- February 27, 2024
Everly Health Partners With National Kidney Foundation, Expands Kidney Health Testing Suite

Everly Health is teaming up with the National Kidney Foundation to improve education around chronic kidney disease, the company announced Monday. In addition, Everly Health is also expanding its diabetes monitoring and kidney health testing suite for health plans and employers. Austin, Texas-based Everly Health is a digital health company for remote diagnostics and managing health conditions. It has three brands: Everlywell, which offers direct-to-consumer at-home health tests; Natalist, which offers fertility and pregnancy products; and Everly Health Solutions, which works with health plans and employers by providing at-home lab tests and virtual care to members and employees. Through the partnership between Everly Health and the National Kidney Foundation, the two organizations will have co-branded educational information about the importance of kidney health screening. Everly’s health plan customers will identify the patients who are at risk of chronic kidney disease, such as being diagnosed with diabetes. Everly Health will ship ...
- Source: https://medcitynews.com/2024/02/kidney-disease-home-testing/
- 101
- February 13, 2024
Announcement of Tasly Bioharma on the Notification of Approval of Drug Clinical Trial

Tasly Bioharma (hereinafter referred to as the “Company”) has received a Notice of Approval for Drug Clinical Trial from the State Drug Administration (hereinafter referred to as the “SDA”) for the project of Human Umbilical Cord Mesenchymal Stem Cell Injection (hereinafter referred to as the “B2278 Injection”), agreeing to carry out the project of Coronary Artery Bypass Grafting (Coronary Artery Bypass Grafting). The Company has received a Notice of Approval for Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection (hereinafter referred to as “B2278 Injection”) from the State Drug Administration (hereinafter referred to as the “SDA”), agreeing to carry out a clinical trial on chronic heart failure caused by chronic ischemic cardiomyopathy with indications of Coronary artery bypass graft (“CABG”). The relevant information is announced as follows: I. Basic information of the drug Drug name: human umbilical cord mesenchymal stem cell injection Dosage form: Injection Specification: 5×107 cells/1 ...
- Source: drugdu
- 111
- January 22, 2024
AcelRx becomes Talphera, adopting new name to reflect pain pivot

AcelRx Pharmaceuticals wants to put a tough few years behind it. After failing to crack the pain market, the biotech has shifted its focus to a pipeline led by a blood thinner and adopted a new name, Talphera, to reflect the revised strategy. The value of AcelRx has fallen sharply in recent memory, dropping 62% over the past year and 98% over the past five years to leave the company with a market cap of below $15 million. The five-year time frame covers the period after the approval of the sublingual pain drug Dsuvia. AcelRx won approval in 2018 but failed to turn the opioid into a major product, generating sales of $1.8 million in 2022. Alora Pharmaceuticals acquired the drug for $1.1 million last year, moving AcelRx away from its earlier focus on pain. Following the transaction, AcelRx’s goals were to win approval tforhe pre-filled ephedrine syringe, Fedsyra, and ...
- Source: drugdu
- 131
- January 12, 2024
Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs

SHANGHAI, Dec. 26, 2023 /PRNewswire/ — Jemincare, a leading pharmaceutical company from China, announced that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., recently received 6 approvals of clinical trials for its innovative drugs in the field of cancer, kidney and anti-infectious diseases, including 4 approvals from National Medical Products Administration (NMPA) and 2 approvals from the U.S. Food & Drug Administration (FDA). On December 20, NMPA has approved a clinical trial for JMKX003801 to treat serious infection caused by Gram-negative bacteria. Drug resistance of antibiotics, especially carbapenem resistance, in Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa has risen year by year. Preclinical studies on its mechanism show that JMKX003801 can overcome carbapenem resistance with very broad antibacterial spectrum. On December 12, NMPA has approved a clinical trial for JMKX003142 to treat renal edema. There are about 120 million patients of chronic kidney disease (CKD) in ...
- Source: drugdu
- 101
- December 30, 2023
Accurate Blood Markers for Identifying AKI Could Eliminate Need for Invasive Kidney Biopsies

Acute Kidney Injury (AKI) is a condition characterized by intense inflammation, leading to sudden kidney function loss. AKI affects an estimated 15% to 20% of hospitalized patients, increasing their risk of in-hospital death and possibly leading to chronic kidney disease requiring dialysis or transplant. Clinicians have long sought markers to detect AKI without resorting to invasive kidney biopsies. Now, researchers have used cells from kidney biopsies to make progress in the search for more accurate and easier-to-obtain markers that can predict, manage, and assess the treatment of AKI. This new study by investigators at Johns Hopkins University (Baltimore, MD, USA) focused on noninvasive assessments of what is termed maladaptive proximal tubule (PT) repair, a process that occurs in response to AKI and is marked by excessive inflammation. This PT maladaptation process offers an opportunity to identify noninvasive markers in blood or urine that could greatly aid in predicting AKI, managing ...
- Source: drugdu
- 200
- December 22, 2023
Calliditas wins over FDA for full approval, broader label on kidney disease drug Tarpeyo

Two years after securing an accelerated approval for its primary immunoglobulin A nephropathy (IgAN) therapy Tarpeyo (budesonide), Calliditas Therapeutics has scored a full FDA endorsement for the oral, delayed-release drug. Tarpeyo becomes the first treatment fully approved in the United States specifically for the chronic autoimmune kidney condition, also known as Berger’s disease. While some graduations from accelerated to full approval are ceremonial, this endorsement carries extra weight as it expands the label for Tarpeyo, allowing it to be accessed by all patients with IgAN. Perviously, the FDA limited the med’s use to those at risk for rapid disease progression. The expansion was facilitated by a confirmatory trial, which was the first phase 3 IgAN study to show significant improvement in estimated glomerular filtration rate (eGFR), which is the most reliable measure of kidney function. The results showed that Tarpeyo can reduce the time to kidney failure by 30%, potentially ...
- Source: drugdu
- 221
- December 22, 2023
MEDICA 2024

Name：MEDICA 2024 Time: Nov 11-14, 2024 Venue: Dusseldorf Exhibition Center City: Dusseldorf/ Germany Product categories: Medical equipment: medical electronic instruments, ultrasound instruments, X-ray equipment, medical optical instruments, clinical examination and analysis instruments, dental equipment and materials, hemodialysis equipment, respiratory equipment, hospital wards, operating rooms, emergency room equipment, hospital office equipment, laboratory equipment, etc. Disposable consumables: disposable medical supplies, dressings and sanitary materials, various surgical instruments, etc. Medical equipment: Medical care equipment, home health care products, physical therapy, plastic surgery technology, etc. Medical periphery: Information and communication technology, medical services and publishing. About MEDICA: The MEDICA exhibition showcases the latest medical equipment, medical supplies, medical technology and services, covering various fields such as hospital equipment, surgical equipment, medical instruments, diagnostic equipment, rehabilitation equipment, and home medical supplies. Exhibitors can showcase their latest medical equipment and services at the fair, showing the strength and technical level of their companies to ...
- Source: drugdu
- 884
- December 20, 2023
CorMedix Wins FDA Approval for Antimicrobial Drug Combo After Two Rejections

By Tristan Manalac The FDA on Wednesday approved CorMedix’s DefenCath (taurolidine and heparin) to reduce catheter-related blood stream infections in adults with kidney failure who are on chronic hemodialysis through a central venous catheter. DefenCath is the first FDA-approved antimicrobial catheter lock solution in the U.S., according to CorMedix’s announcement. CorMedix expects DefenCath to be available in the inpatient setting in the first quarter of 2024. The company’s stock was trading 35% higher Wednesday morning in response to the approval, according to Seeking Alpha. CorMedix CEO Joseph Todisco in a statement said that DefenCath’s approval was a “major advancement” for preventing life-threatening infections and provides doctors “an option to reduce the risk of infections in a patient population already vulnerable due to underlying kidney failure.” DefenCath is a combination of the amino acid derivative taurolidine and the anticoagulant heparin. Taurolidine has demonstrated strong antimicrobial activity against gram-positive and gram-negative bacteria, ...
- Source: drugdu
- 186
- November 18, 2023
The Impact of GLP-1 Weight Loss Drugs on Patients, Healthcare Business

Don Tracy, Associate Editor The rise in popularity of GLP-1 weight-loss drugs, such as Ozempic, Wegovy, and Mounjaro, has had a wide-reaching impact across the healthcare industry and beyond. Image Credit: Adobe Stock Images/Dimid The launch of multiple glucagon-like peptide (GLP-1) drugs for weight loss—such as Ozempic, Wegovy, and Mounjaro—is expected to cause a major shakeup in the stock market, as millions of Americans are set to shed hundreds of millions of pounds over the next decade while reshuffling trillions of dollars in the process, according to expert analysis. Not only have these treatments helped patients shed a significant amount of pounds, but they have also shown efficacy treating other conditions as well. A recent drug trial by Novo Nordisk found that semaglutide, the active ingredient in Ozempic and Wegovy, could help people with kidney failure as well. As shares of Novo Nordisk and Mounjaro developer Eli Lilly increase, dialysis ...
- Source: drugdu
- 111
- November 4, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.